32 results
8-K
SLRN
Acelyrin, Inc.
13 Aug 24
Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results
4:14pm
that the majority of the restructuring charges related to the workforce reduction will be incurred in the third quarter of 2024 and that the implementation
DEF 14A
SLRN
Acelyrin, Inc.
22 Apr 24
Definitive proxy
4:10pm
of a majority of the votes cast on this matter, voting affirmatively or negatively (excluding abstentions and broker non-votes).
“For”
TABLE OF CONTENTS … , must receive “For” votes from a majority of the votes cast on Proposal 2, voting affirmatively or negatively (excluding abstentions and broker non
10-K
2023 FY
EX-97.1
SLRN
Acelyrin, Inc.
28 Mar 24
Annual report
4:21pm
directors, a majority of the independent directors serving on the Board, has made a determination that recoupment would be impracticable. Recoupment
10-K
2e6kg8h5vi 30t1
28 Mar 24
Annual report
4:21pm
10-K
EX-4.3
fw5v6l
28 Mar 24
Annual report
4:21pm
8-K
qtpq7eistg63
11 Mar 24
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
8:05am
8-K
EX-99.2
bzcghr ed6
11 Mar 24
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
8:05am
8-K
EX-99.3
69f92olruoelb0g
11 Mar 24
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
8:05am
8-K
EX-99
6192yxhx9jdmoazeg
7 Nov 23
ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights
4:23pm
8-K
EX-99.1
ap3vv0v xsi
14 Aug 23
ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights
4:22pm
10-Q
lbhhj9yj01b374yevz
15 Jun 23
Quarterly report
4:19pm
8-K
EX-3.1
f2di6qaqrg r4
9 May 23
ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
4:16pm
8-K
EX-3.2
67wcj0mwz02 3jpvdeo
9 May 23
ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
4:16pm
424B4
bx5b g1w3tu7gi9b0
5 May 23
Prospectus supplement with pricing info
4:22pm
S-1/A
EX-3.2
tkucjlal0x 2m
1 May 23
IPO registration (amended)
6:10am